PURPOSE: We describe the current National Cancer Institute chemoprevention agent
development program and provide a summary of the intermediate end points used …

With prostate cancer representing the most common Male cancer and the second most
common cause of cancer‐related death in men in the United States, increasing attention is …

Because prostate cancer is the most common nondermatologic tumor in US men, an
increased focus has been placed on the disease. Dramatic advances have been made in …

Prostate cancer chemoprevention represents a relatively new and promising strategy for
reducing the immense public health burden of this devastating cancer of men in the United …

One randomized, prospective clinical trial for chemoprevention of prostate cancer has been
completed, and two additional trials are ongoing. The investment, time, and effort for these …

A number of early phase trials and three definitive Phase III trials have been conducted in
the field of prostate cancer prevention over the past decade. Although a great deal has been …

Prostate cancer chemoprevention (CP) can be defined as the use of natural and synthetic
agents that inhibit, reverse or regress precancer and delay progression to invasive cancer …

Discussion Level-1 evidence will be needed in order to definitively prove the efficacy of
agents as chemoprevention strategies for prostate cancer. Currently, only finasteride fulfills …

A chemoprevention (CP) strategy has evolved for conducting efficient clinical trials for
prostate cancer (PCa) prevention. It integrates five key components, including agents …

Prostate cancer is an attractive target for chemoprevention because of its ubiquity, treatment-
related morbidity, long latency between premalignant lesions and clinically evident cancer …